[go: up one dir, main page]

MX2017005244A - Regimen de dosificacion para interferon pegilado. - Google Patents

Regimen de dosificacion para interferon pegilado.

Info

Publication number
MX2017005244A
MX2017005244A MX2017005244A MX2017005244A MX2017005244A MX 2017005244 A MX2017005244 A MX 2017005244A MX 2017005244 A MX2017005244 A MX 2017005244A MX 2017005244 A MX2017005244 A MX 2017005244A MX 2017005244 A MX2017005244 A MX 2017005244A
Authority
MX
Mexico
Prior art keywords
dosage regimen
pegylated interferon
interferon
subject
treatment
Prior art date
Application number
MX2017005244A
Other languages
English (en)
Other versions
MX389844B (es
Inventor
Klade Christoph
ZAGRIJTSCHUK Oleh
Chung Lin Ko-
Original Assignee
Pharmaessentia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaessentia Corp filed Critical Pharmaessentia Corp
Publication of MX2017005244A publication Critical patent/MX2017005244A/es
Publication of MX389844B publication Critical patent/MX389844B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describe un interferón tipo I pegilado para uso en el tratamiento de una enfermedad infecciosa, cáncer o enfermedad mieloproliferativa en un sujeto en necesidad del mismo, en donde una dosis de 50 a 540 µg del interferón tipo I pegilado se administra al sujeto a intervalos regulares durante un periodo de tratamiento, el intervalo de 3 a 8 semanas.
MX2017005244A 2014-11-06 2015-11-06 Regimen de dosificacion para interferon pegilado. MX389844B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14192114 2014-11-06
PCT/US2015/059410 WO2016073825A1 (en) 2014-11-06 2015-11-06 Dosage regimen for pegylated interferon

Publications (2)

Publication Number Publication Date
MX2017005244A true MX2017005244A (es) 2017-08-18
MX389844B MX389844B (es) 2025-03-04

Family

ID=51945707

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005244A MX389844B (es) 2014-11-06 2015-11-06 Regimen de dosificacion para interferon pegilado.

Country Status (32)

Country Link
US (3) US11559567B2 (es)
EP (2) EP4282485A3 (es)
JP (2) JP6820841B2 (es)
KR (2) KR102540109B1 (es)
CN (1) CN107530403A (es)
AU (1) AU2015342908B2 (es)
BR (1) BR112017009193A2 (es)
CA (1) CA2964390A1 (es)
CL (1) CL2017001088A1 (es)
DK (1) DK3215193T3 (es)
EA (1) EA037151B1 (es)
ES (1) ES2966888T3 (es)
FI (1) FI3215193T3 (es)
HK (1) HK1243627A1 (es)
HR (1) HRP20231732T1 (es)
HU (1) HUE064909T2 (es)
IL (1) IL251627B (es)
LT (1) LT3215193T (es)
MX (1) MX389844B (es)
MY (1) MY191506A (es)
NZ (1) NZ730924A (es)
PH (1) PH12017500617B1 (es)
PL (1) PL3215193T3 (es)
PT (1) PT3215193T (es)
RS (1) RS65015B1 (es)
SG (1) SG11201702798PA (es)
SI (1) SI3215193T1 (es)
SM (1) SMT202400028T1 (es)
TW (1) TWI737583B (es)
UA (1) UA122867C2 (es)
WO (1) WO2016073825A1 (es)
ZA (1) ZA201702704B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7189399B2 (ja) * 2017-01-18 2022-12-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 骨髄増殖性障害を患う患者の処置のための方法及び医薬組成物
US11414698B2 (en) * 2018-03-22 2022-08-16 Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi Method of quantifying mutant allele burden of target gene
WO2021216801A1 (en) * 2020-04-22 2021-10-28 Southlake Pharmaceuticals, Inc. Pegylated interferon tau and compositions and methods thereof
AU2022221496A1 (en) * 2021-08-29 2023-03-16 Pharmaessentia Corporation Method of Using Pegylated Interferon-alpha

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
AU7408200A (en) * 1999-08-13 2001-03-13 F. Hoffmann-La Roche Ag Mycophenolate mofetil in association with peg-ifn-alpha
CN1501815A (zh) 1999-08-27 2004-06-02 新的干扰素β-样分子
JP2003513681A (ja) 1999-11-12 2003-04-15 マキシゲン・ホールディングス・リミテッド インターフェロンガンマ・コンジュゲート
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
JP2005525302A (ja) 2001-11-20 2005-08-25 ファルマシア・コーポレーション 化学的に修飾されたヒト成長ホルモンコンジュゲート
US20030171285A1 (en) 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
BRPI0306993B8 (pt) 2002-01-18 2021-05-25 Biogen Idec Inc polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível
US7345150B2 (en) 2002-03-26 2008-03-18 Medical University Of Toledo Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
EA200500475A1 (ru) 2002-09-09 2005-10-27 Нектар Терапеутикс Ал, Корпорейшн Водорастворимые полимерные алканалы
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
JP2006519170A (ja) 2002-12-26 2006-08-24 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド サイトカイン、ケモカイン、増殖因子、ポリペプチドホルモン、およびレセプター結合活性が保存されたそのアンタゴニストのポリマー結合体
CN1747748B (zh) 2003-05-23 2011-01-19 尼克塔治疗公司 具有特定原子排列的聚合物衍生物
KR20060120141A (ko) 2003-11-24 2006-11-24 네오스 테크놀로지스, 인크. 글리코페질화 에리트로포이에틴
EP1789092A2 (en) 2004-08-31 2007-05-30 Pharmacia & Upjohn Company LLC Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
US7365127B2 (en) 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
EP1869079A2 (en) 2005-03-11 2007-12-26 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
WO2006094530A1 (en) 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
CN101002944B (zh) 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
EP1834963A1 (en) 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
CN101104078B (zh) 2006-07-11 2011-11-02 北京美倍他药物研究有限公司 多肽及蛋白药物的聚乙二醇偶合物
CN101108895B (zh) 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
WO2008021487A1 (en) * 2006-08-18 2008-02-21 Pepgen Corporation Combination treatment method with interferon-tau
CN1966547B (zh) 2006-11-06 2011-11-09 中国药科大学 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合
CN1970572A (zh) 2006-12-21 2007-05-30 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
CL2008002399A1 (es) 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
DK2186830T3 (da) 2007-09-04 2012-04-02 Biosteed Gene Expression Tech Co Ltd Polyethylenglycol modificeret interferon alpha 2B og fremstillingsfremgangsmåde og applikationer deraf
PT2196475E (pt) 2007-09-04 2012-09-07 Biosteed Gene Expression Tech Co Ltd Interferão alfa-2a modificado por polietilenoglicol, seu processo de síntese e aplicação
CN101491682A (zh) 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 聚乙二醇化重组人干扰素ω偶合物及其制备工艺
CN102131844B (zh) 2008-07-31 2016-03-02 药华医药股份有限公司 肽-聚合物缀合物
CN101671390B (zh) 2008-09-10 2012-10-03 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
CN101514229B (zh) 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物
UA109646C2 (uk) 2009-12-10 2015-09-25 Терапевтичне застосування кон'югатів білка з полімером
AU2011336467A1 (en) 2010-12-01 2013-07-04 Spinal Modulation, Inc. Agent delivery systems for selective neuromodulation

Also Published As

Publication number Publication date
RS65015B1 (sr) 2024-01-31
NZ730924A (en) 2022-04-29
EA037151B1 (ru) 2021-02-11
US20250186552A1 (en) 2025-06-12
BR112017009193A2 (pt) 2018-01-30
ZA201702704B (en) 2020-10-28
ES2966888T3 (es) 2024-04-24
EP3215193B1 (en) 2023-10-04
AU2015342908B2 (en) 2021-06-24
JP2021001184A (ja) 2021-01-07
PT3215193T (pt) 2023-12-15
EP3215193A4 (en) 2018-07-25
CL2017001088A1 (es) 2018-01-12
DK3215193T3 (da) 2024-01-08
EP4282485A2 (en) 2023-11-29
KR20230079520A (ko) 2023-06-07
WO2016073825A1 (en) 2016-05-12
KR20170083074A (ko) 2017-07-17
SG11201702798PA (en) 2017-05-30
JP6820841B2 (ja) 2021-01-27
AU2015342908A1 (en) 2017-05-04
EP4282485A3 (en) 2024-01-17
PH12017500617A1 (en) 2017-09-04
JP2017533192A (ja) 2017-11-09
IL251627A0 (en) 2017-06-29
TWI737583B (zh) 2021-09-01
HUE064909T2 (hu) 2024-04-28
UA122867C2 (uk) 2021-01-13
SI3215193T1 (sl) 2024-02-29
IL251627B (en) 2021-12-01
US11559567B2 (en) 2023-01-24
US20230131552A1 (en) 2023-04-27
FI3215193T3 (fi) 2023-12-28
KR102540109B1 (ko) 2023-06-02
MY191506A (en) 2022-06-28
EP3215193A1 (en) 2017-09-13
EA201790991A1 (ru) 2017-11-30
HK1243627A1 (zh) 2018-07-20
MX389844B (es) 2025-03-04
TW201618808A (zh) 2016-06-01
US20170326206A1 (en) 2017-11-16
PH12017500617B1 (en) 2024-07-03
CN107530403A (zh) 2018-01-02
PL3215193T3 (pl) 2024-03-18
SMT202400028T1 (it) 2024-03-13
KR102724837B1 (ko) 2024-10-31
CA2964390A1 (en) 2016-05-12
LT3215193T (lt) 2024-01-25
HRP20231732T1 (hr) 2024-03-15
US12343381B2 (en) 2025-07-01

Similar Documents

Publication Publication Date Title
SV2018005682A (es) Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
MX2022009352A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
BR112015026325A2 (pt) dosagem oral de compostos glp-1
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX2016013245A (es) Regimen de dosificacion de liberacion inmediata de moduladores s1p.
AR099558A1 (es) Régimen de dosaje del compuesto fgf-18
CY1121566T1 (el) Νευροπροστατευτικο και ενδειξη αυτου
MX2021008738A (es) Regimenes de dosificacion de melflufen para cancer.
CL2017001088A1 (es) Regimen de dosificación para interferón pegilado
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX2022000746A (es) Dimetilfumarato y regimenes de vacunacion.
CL2020000471A1 (es) Regímenes de tratamiento.
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2016007224A (es) Vacuna contra el circovirus porcino tipo 2.
EA202091743A1 (ru) Вакцинация дендритными клетками параллельно с химиотерапией
EA202191327A1 (ru) Лекарственные формы терапевтических препаратов от гриппа
CU20180036A7 (es) Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana
MD4458B1 (ro) Utilizarea preparatului Polibiolină în tratamentul bolnavilor cu ciroză hepatică
UA112089C2 (uk) Тверда лікарська форма комбінованого препарату седативної та снодійної дії, що містить доксиламін
RU2013143983A (ru) Способ коррекции иммунной недостаточности у инфицированного вирусом лейкоза крупного рогатого скота
TN2016000479A1 (en) Nitisinone dosing regimens for the treatment of alkaptonuria.
RU2013109360A (ru) Способ лечения и профилактики желудочно-кишечных заболеваний новорожденных телят